This study is testing if a combination of two medicines, belimumab and rituximab, is more effective than rituximab alone for adults with primary membranous nephropathy (a kidney disease where your immune system attacks your kidneys, causing protein loss in urine). Researchers want to see if this combination can help more people achieve complete or partial remission (improvement) of their condition. You may be able to join if you are between 18 and 75 years old and have primary membranous nephropathy confirmed by a kidney biopsy. The study aims to enroll 58 participants and will measure how many achieve remission after 104 weeks.

Study design

This is an interventional study with an unspecified phase, involving 58 participants. It includes an open-label phase (Part A) where all participants receive belimumab, followed by a comparison of belimumab and rituximab versus rituximab alone.

What's involved

Participants in Part A will receive weekly subcutaneous belimumab for 52 weeks, along with two doses of intravenous rituximab at weeks 4 and 6. Blood samples will be taken weekly for the first four doses of belimumab.

Compensation

Not stated in the trial record.

Follow-up

Participants are followed after the 52-week treatment period on no study medication until week 156. The primary outcome is measured at Week 104.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.